About Editas Medicine
Editas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: EDIT
- Previous Close: $23.54
- 50 Day Moving Average: $19.58
- 200 Day Moving Average: $16.82
- 52-Week Range: $35,634,000.00 - $12.43
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.47
- P/E Growth: 0.00
- Market Cap: $838.82M
- Outstanding Shares: 35,634,000
- Net Margins: -1,184.46%
- Return on Equity: -59.22%
- Return on Assets: -31.66%
Companies Related to Editas Medicine:
- Debt-to-Equity Ratio: 0.19%
- Current Ratio: 14.80%
- Quick Ratio: 14.80%
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?
5 brokers have issued 1-year target prices for Editas Medicine's stock. Their forecasts range from $28.00 to $40.00. On average, they anticipate Editas Medicine's share price to reach $33.75 in the next year.
When will Editas Medicine announce their earnings?
Editas Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.
What are analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)
According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (1/10/2017)
Who owns Editas Medicine stock?
Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.43%), Viking Global Investors LP (4.80%), Deerfield Management Co. (4.80%), EcoR1 Capital LLC (1.76%), Foresite Capital Management III LLC (0.77%) and State Street Corp (0.30%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co.
Who sold Editas Medicine stock? Who is selling Editas Medicine stock?
Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Clarius Group LLC. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co.
Who bought Editas Medicine stock? Who is buying Editas Medicine stock?
Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Foresite Capital Management III LLC, Highland Capital Management LP, Clough Capital Partners L P, A.R.T. Advisors LLC, Russell Investments Group Ltd., FMR LLC and State Street Corp.
How do I buy Editas Medicine stock?
Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Editas Medicine stock cost?
One share of Editas Medicine stock can currently be purchased for approximately $23.54.